Abstracts tagged "B-Lymphocyte"

Abstract Number: L16 • ACR Convergence 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Megan Clowse¹, David Isenberg², Joan Merrill³, Thomas Dörner⁴, Michelle Petri⁵, Edward Vital⁶, Eric Morand⁷, Teri Jimenez⁸, Stephen Brookes⁹, Janine Gaiha-Rohrbach¹⁰, Christophe Martin¹¹, Annette Nelde¹² and Christian Stach¹³, ¹Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁸UCB, Raleigh, NC, ⁹Biogen, Maidenhead, United Kingdom, ¹⁰Biogen, Cambridge, MA, ¹¹UCB, Slough, United Kingdom, ¹²Biogen, Baar, Switzerland, ¹³UCB, Monheim am Rhein, Germany
Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
Abstract Number: 0346 • ACR Convergence 2024
Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls
Amelia Sawyers¹, Leslie Crofford², Erin Wilfong³ and Rachel Bonami³, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a collection of rare, systemic rheumatic diseases. A role for B cells in IIM is indicated by the success…
Abstract Number: 1648 • ACR Convergence 2024
In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells
Giulia Frazzei¹, Ana Merino Vico², Jan Piet van Hamburg², Ronald Van Vollenhoven³ and Sander Tas⁴, ¹Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis and are associated with disease severity. Detailed analysis of ACPApos B cells…
Abstract Number: 2498 • ACR Convergence 2024
The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis
Veronica Pulito-Cueto¹, Joao Carlos Batista-Liz¹, Laura Carmen Terron², Iván Fernández Rengel³, María Sebastián Mora-Gil⁴, María Teresa Leonardo⁵, Ana Peñalba⁵, Luis Martín-Penagos⁶, Lara Belmar-Vega⁷, Cristina Gomez-Fernandez⁸, Ligia Gabrie-Rodriguez⁹, Rafael Gálvez Sánchez⁹, Luis Caminal-Montero¹⁰, Ana Turrion Nieves¹¹, Patricia Quiroga Colina¹², Esther Vicente-rabaneda¹³, Belén Sevilla-Pérez¹⁴, José Luis Callejas¹⁵, Eduardo Andrés-León², Javier Martin¹⁶, Ana María Marquez¹⁷, Santos Castañeda¹³, Ricardo Blanco-Alonso¹⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Unidad de Bioinformática, Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Granada, Spain, ³Bioinformatics Unit, Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC, GENYO, Cen, Granada, Spain, ⁴Immunopathology Group, IDIVAL, Santander, Spain, ⁵Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, ⁸Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ¹¹Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁵Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁶Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, ¹⁷Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Nephritis is the main cause of long-term morbidity and mortality in patients with Immunoglobulin-A vasculitis (IgAV) [1, 2]. Unfortunately, sensitive, specific, and non-invasive biomarkers…
Abstract Number: 0424 • ACR Convergence 2024
The Clinical Utility of Serum BAFF Levels in Pregnant Patients with SLE
Catherine Sims¹, Amanda Eudy², Samir Soneji³, Kateena Addae-Konadu³, Jennifer Gilner³, Andra James³, Jerome Federspiel⁴, Eugene Kovalik³, Anika Lucas⁴, Laura Neil⁵, Amanda Snyderman³ and Megan Clowse⁶, ¹Duke University, Knightdale, NC, ²Duke University, Raleigh, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Durham, ⁶Duke University, Chapel Hill, NC
Background/Purpose: The B cell Activating Factor (BAFF) signaling pathway plays an important role in the selection, maturation, and survival of B cells; it consequently contributes…
Abstract Number: 1649 • ACR Convergence 2024
B Cell Subset Contribution to Autoantibodies in Lupus
Kristina Ottens¹, Jalyn Schneider¹ and Anne Satterthwaite², ¹UT Southwestern Medical Center, Dallas, ²UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Systemic lupus erythematous is characterized by the production of pathogenic autoantibodies that drive inflammation and tissue damage. Defining the B cell subsets that give…
Abstract Number: 2599 • ACR Convergence 2024
Xist Deletion in B Cells Results in Systemic Lupus Erythematosus Phenotypes
Claudia Lovell¹, Nikhil Jiwrajka², Hayley Amerman³, Michael Cancro⁴ and Montserrat Anguera⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, ⁴Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) exhibits a strong female sex bias but the mechanisms underlying this bias are not well understood. Epidemiological studies demonstrate that…
Abstract Number: 0779 • ACR Convergence 2024
Sex Differences in the B Cell Compartment of Patients with Oligoarticular Juvenile Idiopathic Arthritis
Ki Pui Lam¹, Claudia Harris¹, Daniela Fernandez-Salinas¹, Maryrose Hahn², Maryam Ashoor³, Ahmad Bakhsh¹, Carrie Bryant¹, Siobhan Case¹, Mia Chandler⁴, Joyce Chang⁵, Ezra Cohen¹, Fatma Dedeoglu³, Olha Halyabar¹, Jonathan Hausmann¹, Melissa Hazen³, Daniel Ibanez¹, Liyoung Kim¹, Jeffrey Lo³, Mindy Lo³, Esra Meidan⁶, Megan Perron¹, Helene Powers¹, Mary Beth Son⁵, Holly Wobma⁷, Pui Lee⁸, Peter Nigrovic⁵, Laurie Ohlms⁹, Margaret Chang³, Maria Gutierrez-Arcelus³ and Lauren Henderson¹⁰, ¹Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Georgetown, MA, ³Boston Children's Hospital, boston, MA, ⁴Boston Children’s Hospital, Boston, MA, ⁵Boston Children's Hospital, Brookline, MA, ⁶Boston Children's Hospital, Somerville, MA, ⁷Division of Immunology, Boston Children's Hospital, Boston, MA, ⁸Boston Children's Hospital, Newton, MA, ⁹Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital, Harvard Medical School, Boston, MA, ¹⁰Boston Children's Hospital, Watertown, MA
Background/Purpose: T peripheral helper (Tph) cells accumulate in the joints of children with ANA+ oligoarticular juvenile idiopathic arthritis (oligo JIA) and may provide pathogenic help…
Abstract Number: 1650 • ACR Convergence 2024
IL-33 Expands Plasma Cells, Disrupts Germinal Centers and Increases Autoantibody Production
Andre Limnander¹, Eva Conde¹, Seblewongel Asrat², Andrea Vecchione², Kaitlyn Gayvert², Paulina Pedraza², Carley Tasker², Sharon Huang², Dmitry Yarilin², Dylan Birchard², Li-Hong Ben², Wei Keat Lim², Andrew Murphy², Matthew Sleeman² and Jamie orengo¹, ¹Regeneron Pharmaceuticals, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: IL-33 is a pro-inflammatory cytokine that plays a role in asthma, COPD and autoimmune diseases. The role of IL-33 on B cell maturation and…
Abstract Number: 0780 • ACR Convergence 2024
Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy
Carlo Tur¹, Markus Eckstein², Velden Joachim³, Christina Bergmann⁴, Janina Auth¹, Laura Bucci¹, Giulia Corte⁵, Melanie Hagen¹, Andreas Wirsching¹, Ricardo Grieshaber-Bouyer¹, Petra Reis¹, Nicolai Kittan¹, Jochen Wacker¹, Simon Rauber¹, Aleix Rigau⁶, Andreas Ramming¹, Maria Antonietta D'Agostino⁷, Arndt Hartmann⁸, Fabian Müller⁹, Andreas MAckensen¹⁰, Aline Bozec¹, Georg Schett¹¹ and Maria Gabriella Raimondo¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ⁶Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁸Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹⁰Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has proved potential for achieving long-term drug-free remission in patients with autoimmune diseases (AIDs). Its effectiveness likely…
Abstract Number: 1651 • ACR Convergence 2024
Unlocking the Secrets of Breg Dysfunction in Lupus: Glycosylation Patterns as Therapeutic Targets
Pauline Kerleroux-Trébaol¹, Marie Morel¹, Sandrine Jousse-Joulin², Divi Cornec³, Pierre Pochard¹ and Anne Bordron¹, ¹Université de Bretagne Occidentale, brest, France, ²cavale blanche hospital, brest, France, ³Service de Rhumatologie, CHU de Brest, Brest, France
Background/Purpose: The immune system is a complex network of cells preventing the invasion of the organism from external particles. The break in the homeostasis will…
Abstract Number: 0811 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis
Benjamin Jones¹, Rufei Lu², Andrea Fava³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steven Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Judith James¹³ and Joel Guthridge¹³, ¹Oklahoma State University, Oklahoma City, OK, ²University of California San Francisco, San Bruno, CA, ³Johns Hopkins University, Baltimore, MD, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus nephritis (LN) can lead to severe morbidity and early mortality in SLE patients. While therapeutic options for LN have improved, they are not…
Abstract Number: 1679 • ACR Convergence 2024
Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study
Nathanial Eddy¹, Jane Buckner², Paul Emery³, Michael Weinblatt⁴, Vivian Bykerk⁵, Andrew Cope⁶, Gerd Burmester⁷, Yoshiya Tanaka⁸, Gustavo Citera⁹, Peter Nash¹⁰, Quentin Dornic¹¹, Peter Schafer¹², Sheila Kelly¹³, Michael Maldonado¹¹ and Jinqi Liu¹¹, ¹Bristol Myers Squibb, Princeton, ²Benaroya Research Institute, Seattle, WA, ³University of Leeds, Leeds, United Kingdom, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Hospital For Special Surgery, New York, NY, ⁶King's College London, London, United Kingdom, ⁷Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ¹⁰Griffith University, Brisbane, Australia, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, BELLE MEAD, NJ, ¹³Bristol Myers Squibb, Doylestown, PA
Background/Purpose: Despite considerable advances in pharmacologic approaches to RA management, a better understanding of the underlying immunopathology is still needed.1,2 A dysregulated immune system is…
Abstract Number: 0836 • ACR Convergence 2024
NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses
Jee Ho Lee¹, Manisha Mohandoss², Lichchavi Rajasinghe¹, Silvia Preite³, Katie Madore², Mark Birrell⁴, Jan Piet van Hamburg⁵, Sander Tas⁶, Matthew Perry³, Tatiana Ort¹ and Gary Sims¹, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaitherburg, ³Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁴Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, london, United Kingdom, ⁵Amsterdam UMC, Amsterdam, Netherlands, ⁶Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: T follicular helper (Tfh) cells are a specialized CD4+ T cell subset which can help B cells in the germinal center (GC) to drive…
Abstract Number: 1775 • ACR Convergence 2024
Childhood-onset Sjögren Disease Has an Altered Peripheral Blood Immune Landscape Compared to Adult-onset Disease Characterized by Activated CD4+ T-cells Which Could Drive B-cell Dysregulation
Junjie Peng, Lucia Martin-Gutierrez, George Robinson, Elizabeth Jury and Coziana Ciurtin, University College London, London, United Kingdom
Background/Purpose: Childhood-onset Sjögren Disease (cSjD) is a rare, poorly understood autoimmune rheumatic disease with onset before 18 years. Differences in clinical presentation compared to adults/lack…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].